About Curapath
Curapath is a company based in Paterna (Spain) founded in 2013 was acquired by Arcline in April 2021. Curapath offers products and services including Pre-Clinical Services, Clinical Services, Commercial Services, and Polymer and Lipid Excipients. Curapath operates in a competitive market with competitors including Flashpoint Therapeutics, Biocydex, Vim Meditech, Magle Group and DNA Nanobots, among others.
- Headquarter Paterna, Spain
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$14.07 K (USD), Grant
Jan 01, 2020
-
Investors
European Union
& 1 more
-
Employee Count
Not available
-
Acquired by
Arcline
(Apr 27, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Curapath
Curapath offers a comprehensive portfolio of products and services, including Pre-Clinical Services, Clinical Services, Commercial Services, and Polymer and Lipid Excipients.
Offers formulation screening and testing for early-stage therapeutics.
Produces GMP-compliant batches for clinical trials.
Provides regulatory support for large-scale manufacturing.
Supplies materials for enhancing drug stability and bioavailability.
Funding Insights of Curapath
Investors in Curapath
Curapath has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union and Arcline Investment Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Arcline Investment Management is focused on investing in critical industries.
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Curapath
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Curapath
Investment portfolio details for Curapath
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Curapath
Detailed financials for Curapath
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Curapath Comparisons
Peer comparison for Curapath
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Curapath
Curapath operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flashpoint Therapeutics, Biocydex, Vim Meditech, Magle Group and DNA Nanobots, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Flashpoint Therapeutics is developing nanotherapeutic candidates that can deliver precise RNA, DNA, and peptide payloads to specific cells at the right time.
|
|
| Locked | Locked | Locked |
Preclinical drug discovery, formulation and drug delivery R&D services
|
|
| Locked | Locked | Locked |
Specializes in developing and manufacturing innovative parenteral drug delivery systems and sterile injectables.
|
|
| Locked | Locked | Locked |
Develops medical technologies for pharmaceuticals, therapeutics, and biopolymers.
|
|
| Locked | Locked | Locked |
Targeted chemotherapy, vaccines, and gene therapy are delivered via nanotechnology.
|
Detailed competitors of Curapath
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Curapath
Complete news archive for Curapath
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Curapath
Curapath was founded in 2013 and raised its 1st funding round 7 years after it was founded.
Curapath is headquartered in Paterna, Spain. It is registered at Paterna, Valencian Community, Spain.
Developer of drug delivery systems for therapeutic purposes. The company specializes in the design, development, and custom manufacturing of poly amino acid-and lipid-based nanoparticle delivery systems for therapeutics and vaccines.
Curapath's top competitors include Flashpoint Therapeutics, DNA Nanobots and Biocydex.
Curapath offers Pre-Clinical Services, Clinical Services, Commercial Services, and Polymer and Lipid Excipients.
Curapath has 2 investors. Key investors include European Union, and Arcline Investment Management.